Inositec AG

9 articles about Inositec AG

• Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG

  11/22/2021

  Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company focused on treatments for end-stage kidney disease patients with progressive vascular calcification disorders, and Inositec AG, a Swiss company, developing first-in-class non-dialysis treatments for soft tissue and vascular calcification disorders.

• 

  Vifor Pharma Doubles Down on Kidney Disease with New Acquisitions

  11/22/2021

  Switzerland-based Vifor Pharma is acquiring Spain’s Sanifit Therapeutics and another Swiss company, Inositec.
• 

  BioSpace Movers & Shakers, Oct. 9

  10/9/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Inositec Appoints Serial Entrepreneur and Cardiologist Michael H. Davidson to Board of Directors

  10/7/2020

  Inositec, a pioneer in the development of life-saving small molecule drugs for calcification disorders such as aortic valve stenosis, announced that Michael H. Davidson, MD, has been appointed to the Board of Directors.

• Inositec Granted US Composition of Matter Patent for Cardiovascular Calcification Inhibitor INS-3001

  5/4/2020

  Inositec, a pioneer in the development of life-saving small molecule drugs based on the natural compound inositol hexaphosphate, announced that the U.S. Patent and Trademark Office has issued a patent covering its platform of inositol phosphate analogs and specifically INS-3001, an inhibitor of pathological soft tissue calcification.

• Inositec’s INS-3001 Significantly Reduces Cardiovascular Calcification in Proof-of-Concept Studies Published in Nature Communications

  2/5/2020

  Inositec, a pioneer in the development of life-saving small molecule drugs based on myo-inositol hexaphosphate, announced that positive proof-of-concept data on INS-3001, a novel cardiovascular calcification inhibitor, were published in Nature Communications.

• Inositec’s INS-3001 Significantly Reduces Vascular Calcification Data Presented at Kidney Week 2018 Indicates

  10/26/2018

  Inositec announced today that INS-3001, a novel vascular calcification inhibitor, demonstrated the ability to significantly inhibit the calcification process in preclinical studies.

• Inositec AG Appoints Dr Frits van Alphen as Chief Medical Officer

  1/18/2018

  Dr van Alphen has over 20 years of experience in clinical development and medical affairs, employed in roles of increasing responsibility.

• Inositec AG Secures CHF1.4 Million In Seed Financing To Advance New Class Of Inositol Hexaphosphate-Based Drug Candidates

  10/27/2016